Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11278365rdf:typepubmed:Citationlld:pubmed
pubmed-article:11278365lifeskim:mentionsumls-concept:C0020792lld:lifeskim
pubmed-article:11278365lifeskim:mentionsumls-concept:C0205145lld:lifeskim
pubmed-article:11278365lifeskim:mentionsumls-concept:C1801960lld:lifeskim
pubmed-article:11278365lifeskim:mentionsumls-concept:C0061817lld:lifeskim
pubmed-article:11278365lifeskim:mentionsumls-concept:C1979853lld:lifeskim
pubmed-article:11278365pubmed:issue18lld:pubmed
pubmed-article:11278365pubmed:dateCreated2001-4-30lld:pubmed
pubmed-article:11278365pubmed:abstractTextComponents of vascular basement membrane are involved in regulating angiogenesis. Recently, tumstatin (the NC1 domain of alpha3 chain of type IV collagen) was identified as possessing anti-angiogenic activity. In the present study, the anti-angiogenic activity of tumstatin was localized to the putative 54-132-amino acid Tum-5 domain, and the activity mediated by alpha(v)beta(3) integrin interaction in an RGD-independent manner. The recombinant Tum-5 produced in Escherichia coli and Pichia Pastoris specifically inhibited proliferation and caused apoptosis of endothelial cells with no significant effect on nonendothelial cells. Tum-5 also inhibited tube formation of endothelial cells on Matrigel and induced G1 endothelial cell cycle arrest. Moreover, anti-angiogenic effect of Tum-5 was also examined in vivo using both a Matrigel plug assay in C57BL/6 mice and human prostate cancer (PC-3) xenografts in nude mice. The in vivo results demonstrate that Tum-5 at 1 mg/kg significantly inhibited growth of PC-3 tumors in association with a decrease in CD31 positive vasculature. These in vivo studies also show that, at molar equivalents, human Tum-5 is at least 10-fold more active than human endostatin. In addition, these studies for the first time suggest that through the action of endogenous inhibitors, alpha(v)beta(3) integrin may also function as a negative regulator of angiogenesis. Taken together, these findings demonstrate that Tum-5, a domain derived from tumstatin, is an effective inhibitor of tumor-associated angiogenesis and a promising candidate for the treatment of cancer.lld:pubmed
pubmed-article:11278365pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11278365pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11278365pubmed:languageenglld:pubmed
pubmed-article:11278365pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11278365pubmed:citationSubsetIMlld:pubmed
pubmed-article:11278365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11278365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11278365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11278365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11278365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11278365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11278365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11278365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11278365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11278365pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11278365pubmed:statusMEDLINElld:pubmed
pubmed-article:11278365pubmed:monthMaylld:pubmed
pubmed-article:11278365pubmed:issn0021-9258lld:pubmed
pubmed-article:11278365pubmed:authorpubmed-author:ManfrediMMlld:pubmed
pubmed-article:11278365pubmed:authorpubmed-author:ReimerCClld:pubmed
pubmed-article:11278365pubmed:authorpubmed-author:MaeshimaYYlld:pubmed
pubmed-article:11278365pubmed:authorpubmed-author:KharbandaSSlld:pubmed
pubmed-article:11278365pubmed:authorpubmed-author:KalluriRRlld:pubmed
pubmed-article:11278365pubmed:authorpubmed-author:HopferHHlld:pubmed
pubmed-article:11278365pubmed:authorpubmed-author:HolthausK AKAlld:pubmed
pubmed-article:11278365pubmed:authorpubmed-author:ChandamuriB...lld:pubmed
pubmed-article:11278365pubmed:issnTypePrintlld:pubmed
pubmed-article:11278365pubmed:day4lld:pubmed
pubmed-article:11278365pubmed:volume276lld:pubmed
pubmed-article:11278365pubmed:ownerNLMlld:pubmed
pubmed-article:11278365pubmed:authorsCompleteYlld:pubmed
pubmed-article:11278365pubmed:pagination15240-8lld:pubmed
pubmed-article:11278365pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:11278365pubmed:meshHeadingpubmed-meshheading:11278365...lld:pubmed
pubmed-article:11278365pubmed:meshHeadingpubmed-meshheading:11278365...lld:pubmed
pubmed-article:11278365pubmed:meshHeadingpubmed-meshheading:11278365...lld:pubmed
pubmed-article:11278365pubmed:meshHeadingpubmed-meshheading:11278365...lld:pubmed
pubmed-article:11278365pubmed:meshHeadingpubmed-meshheading:11278365...lld:pubmed
pubmed-article:11278365pubmed:meshHeadingpubmed-meshheading:11278365...lld:pubmed
pubmed-article:11278365pubmed:meshHeadingpubmed-meshheading:11278365...lld:pubmed
pubmed-article:11278365pubmed:meshHeadingpubmed-meshheading:11278365...lld:pubmed
pubmed-article:11278365pubmed:meshHeadingpubmed-meshheading:11278365...lld:pubmed
pubmed-article:11278365pubmed:meshHeadingpubmed-meshheading:11278365...lld:pubmed
pubmed-article:11278365pubmed:meshHeadingpubmed-meshheading:11278365...lld:pubmed
pubmed-article:11278365pubmed:meshHeadingpubmed-meshheading:11278365...lld:pubmed
pubmed-article:11278365pubmed:meshHeadingpubmed-meshheading:11278365...lld:pubmed
pubmed-article:11278365pubmed:meshHeadingpubmed-meshheading:11278365...lld:pubmed
pubmed-article:11278365pubmed:meshHeadingpubmed-meshheading:11278365...lld:pubmed
pubmed-article:11278365pubmed:year2001lld:pubmed
pubmed-article:11278365pubmed:articleTitleIdentification of the anti-angiogenic site within vascular basement membrane-derived tumstatin.lld:pubmed
pubmed-article:11278365pubmed:affiliationDepartment of Medicine and the Cancer Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA.lld:pubmed
pubmed-article:11278365pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11278365pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:11278365pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11278365lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11278365lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11278365lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11278365lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11278365lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11278365lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11278365lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11278365lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11278365lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11278365lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11278365lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11278365lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11278365lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11278365lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11278365lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11278365lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11278365lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11278365lld:pubmed